The Egyptian Drug Authority (EDA) has published the Egyptian Guidelines on the CTD Quality Module for Human Pharmaceuticals (Version 2, 2023) — a regulatory framework that defines the structure, content, and documentation requirements for preparing the Quality Module (Module 3) of marketing authorization dossiers for human pharmaceutical products in Egypt.
Objective and Scope
The guideline provides clear instructions on how applicants should prepare the Common Technical Document (CTD) Quality Module. It applies to all human pharmaceutical products submitted for evaluation by the EDA and ensures that dossiers meet regulatory expectations for quality, safety, and efficacy based on internationally recognized standards.
Regulatory Basis and Flexibility
The guideline aligns with ICH CTD principles and serves as a reference for national regulatory evaluation while allowing the EDA to request additional information as necessary based on current scientific knowledge. Applicants may also use alternative approaches if they are scientifically and technically justified.
Module 3 Structure and Content Requirements
The CTD Quality Module is structured to present all quality-related data for both the drug substance (API) and drug product (FPP) in a systematic format.
1- Drug Substance (API) Requirements The guideline details essential information that must be included for the drug substance, including:
General Information: Chemical identity, nomenclature, structure, and properties.
Key Principles and International Alignment
The guideline adopts key principles from ICH M4Q and related international standards, helping ensure that regulatory submissions in Egypt are consistent with global dossier expectations. It draws on well-established references such as ICH Q1 (stability), Q2 (analytical validation), Q3 (impurities), and others, ensuring a scientifically sound structure for quality data.
Key Takeaway
The EDA CTD Quality Module Guideline Version 2 provides a detailed framework for structuring the quality section of regulatory dossiers for human pharmaceuticals in Egypt. By aligning with internationally accepted CTD standards, the guideline enhances regulatory clarity, supports higher dossier quality, and contributes to more predictable and efficient evaluation outcomes.
